Tag: pharmaceuticals

  • Brand-Name Statin Use Tied to High Cost of Unneeded Care

    Researchers from medical centers in New York and San Francisco found that nearly 87 percent of the estimated $6.7 billion spent in one year on unnecessary tests or medications in primary care, is consumed by brand-name statins to treat high cholesterol. The findings appear in a research letter in the 1 October online issue of…

  • Small Business Grant Awarded for Bone Marrow Protection Drug

    A company in Chapel Hill, North Carolina has received a $3 million grant from NIH to commercialize a therapy to protect bone marrow in cancer patients against damage from chemo and radiation therapy. G-Zero Therapeutics received the Small Business Innovation Research (SBIR) grant from the National Institute of Allergy and Infectious Diseases. The award to…

  • Math Methods Devised to Design Chemical Catalysts

    Research chemists at University of Utah in Salt Lake City have developed a process based on mathematics to design chemical catalysts, including those for making drugs. Professor Matt Sigman (pictured right) and doctoral student Kaid Harper report their findings in this week’s issue of the journal Science; paid subscription required. Catalysts are substances that encourage…

  • Genomics Consortium Adds Two Members, Gains $49 Million

    The Structural Genomics Consortium (SGC) says it added two new pharmaceutical companies as members and $48.9 million in new funding. The partnership of drug companies and science funding agencies conducts basic drug discovery research, with its findings released to the public domain. SGC added Eli Lilly Canada and Pfizer Inc. to its membership that also…

  • Drug Company Stock Prices Linked to Cancer Trial Results

    A study indicates that changes in stock prices of companies in phase 3 clinical trials of their cancer drugs were associated with the outcomes of those trials in the period before the results were publicly announced. The findings of Allan Desky of Mount Sinai Hospital in Toronto, Canada and colleagues appear online in the Journal…

  • Roche, Canadian Not-for-Profit to Partner on New Drugs

    The Centre for Drug Research and Development (CDRD) in Vancouver, Canada and Swiss pharmaceutical maker F. Hoffmann-La Roche Ltd. have agreed to collaborate on development and commercialization of new drug therapies. The exact therapies are yet to be defined, according to the announcement, but will be “for the treatment of diseases with high unmet medical…

  • U.S. Biotech Gets Approval for Stem Cell Trial in Europe

    Advanced Cell Technology Inc. in Marlborough, Massachusetts has received clearance from authorities in the U.K. to begin treating patients with compounds derived from human embryonic stem cells (hESCs) as part of a clinical trial. The approval from the U.K. Medicines and Healthcare Products Regulatory Agency involves a test of retinal pigment epithelium (RPE) from hESCs…

  • University Spin-Off Begins Trial of Stem Cell ALS Treatment

    A technology developed at Tel Aviv University in Israel and licensed to a spin-off company invokes the potential of bone-marrow stem cells as treatment for amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease. A clinical trial, now in Israel and later in the U.S., to test the discovery is recruiting participants. The technology…

  • Superbug Therapy Based on University Research in Development

    MGB Biopharma, a biotechnology company in Glascow, U.K., is developing a new antibiotic treatment for resistant infections including MRSA and Clostridium Difficile (C. Diff.) bugs. The company licensed the discoveries from labs at University of Strathclyde, also in Scotland, that they are developing into oral and IV -administered drugs. C. Diff. is a bacterium that…

  • University Licenses Cancer Drug Screening Technology

    A technology developed at University of Colorado in Boulder to screen drug compounds for potential cancer treatments has been licensed by the university to a Boulder start-up company. Suvica Inc. will develop the patented drug discovery technology into a marketable product. The drug discovery processes licensed to Suvica use a genetically modified Drosophila fruit fly…